FDA approves Valchlor for cutaneous T-Cell Lymphoma
Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced that the FDA has granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type Cutaneous T-cell Lymphoma (CTCL) in patients who have received prior skin-directed therapy. Valchlor is the first and only FDA-approved topical formulation of mechlorethamine, commonly known as nitrogen mustard. Valchlor is a gel that is applied topically once a day and dries on the skin.
On July 30, 2013, Ceptaris signed an agreement to merge with Actelion US Holding Company, a subsidiary of Actelion Ltd. The approval of Valchlor is a condition of closing the merger.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins